The estimated Net Worth of Stuart A Arbuckle is at least $101 Millón dollars as of 21 June 2024. Mr. Arbuckle owns over 3,000 units of Vertex Pharmaceuticals stock worth over $1,424,220 and over the last 12 years he sold VRTX stock worth over $92,482,267. In addition, he makes $6,859,530 as Executive Vice President y Chief Commercial Officer at Vertex Pharmaceuticals.
Stuart has made over 97 trades of the Vertex Pharmaceuticals stock since 2013, according to the Form 4 filled with the SEC. Most recently he exercised 3,000 units of VRTX stock worth $1,424,220 on 21 June 2024.
The largest trade he's ever made was selling 101,875 units of Vertex Pharmaceuticals stock on 19 July 2017 worth over $16,452,813. On average, Stuart trades about 6,426 units every 29 days since 2012. As of 21 June 2024 he still owns at least 3,000 units of Vertex Pharmaceuticals stock.
You can see the complete history of Mr. Arbuckle stock trades at the bottom of the page.
Stuart A. Arbuckle is Executive Vice President, Chief Commercial Officer of Vertex Pharmaceuticals Incorporated. Mr. Arbuckle is our Executive Vice President and Chief Commercial Officer, a position he has held since September 2012. Prior to joining us, Mr. Arbuckle held multiple commercial leadership roles at Amgen, Inc., a 17,000 person biotechnology company, from July 2004 through August 2012. Mr. Arbuckle has worked in the biopharmaceuticals industry since 1986, including more than 15 years at GlaxoSmithKline plc, where he held sales and marketing roles of increasing responsibility for medicines aimed at treating respiratory, metabolic, musculoskeletal, cardiovascular and other diseases. He served as a member of the Board of Directors of Cerulean Pharma, Inc. from June 2015 through July 2017 and has served as a member of the Board of Directors of ImmunoGen, Inc. since January 2018. Mr. Arbuckle holds a BSc in pharmacology and physiology from the University of Leeds.
As the Executive Vice President y Chief Commercial Officer of Vertex Pharmaceuticals, the total compensation of Stuart Arbuckle at Vertex Pharmaceuticals is $6,859,530. There are 1 executives at Vertex Pharmaceuticals getting paid more, with Jeffrey Leiden having the highest compensation of $18,790,000.
Stuart Arbuckle is 54, he's been the Executive Vice President y Chief Commercial Officer of Vertex Pharmaceuticals since 2012. There are 11 older and 11 younger executives at Vertex Pharmaceuticals. The oldest executive at Vertex Pharmaceuticals, Inc. is William Young, 75, who is the Independent Director.
Stuart's mailing address filed with the SEC is 222 BERKELEY STREET, 12TH FLOOR, , BOSTON, MA, 02116.
Over the last 21 years, insiders at Vertex Pharmaceuticals have traded over $934,925,905 worth of Vertex Pharmaceuticals stock and bought 308,652 units worth $12,298,449 . The most active insiders traders include Lloyd Carney, Jeffrey M Leiden y Joshua S Boger. On average, Vertex Pharmaceuticals executives and independent directors trade stock every 5 days with the average trade being worth of $4,747,875. The most recent stock trade was executed by Jeffrey M Leiden on 30 August 2024, trading 3,784 units of VRTX stock currently worth $1,888,216.
Vertex Pharmaceuticals is an American biopharmaceutical company based in Boston, Massachusetts. It was one of the first biotech firms to use an explicit strategy of rational drug design rather than combinatorial chemistry.
Vertex Pharmaceuticals executives and other stock owners filed with the SEC include: